SpyGlass Pharma, Inc. is a clinical-stage biopharmaceutical company based in Aliso Viejo, California, that develops treatments for chronic eye conditions. The company focuses on long-acting, sustained drug-delivery implants designed to provide continuous medication to the eye. Its proprietary platform utilizes non-bioerodible drug pads attached to an intraocular lens (IOL) to deliver approved medicines directly to targeted ocular tissues. The company's lead product candidate, the BIM-IOL System, is designed to be implanted during routine cataract surgery to deliver bimatoprost for up to three years, reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. SpyGlass is also developing a non-IOL-based, ring-shaped implant for patients not undergoing cataract surgery. By providing continuous, multi-year drug elution, the company aims to eliminate the need for daily topical eye drops and improve patient adherence.
